ALL

(n = 54)

TKI-HT (−)

(n = 13)

TKI-HT (+)

(n = 41)

P-value

Age, mean (SD)

67.0

60.3 (13.0)

68.1 (8.4)

0.06

≥ 65, n (%)

35 (64.8)

6 (46.2)

29 (70.7)

0.08

Sex (male/female), n (%)

13/41 (24.0/75.9)

2/11 (15.3/84.6)

11/30 (26.8/73.1)

0.48

BMI (kg/m²), mean (SD)

21.5

21.8 (3.5)

21.2 (3.8)

0.58

BMI ≥ 25, n (%)

9 (16.7)

1 (7.7)

8 (19.5)

0.43

Medical history

Hypertension, n (%)

18 (33.3)

2 (15.4)

16 (39.0)

0.18

Diabetic mellites, n (%)

8 (14.8)

2 (15.4)

6 (14.6)

1.00

Hyperlipidemia, n (%)

5 (9.3)

1 (7.7)

4 (9.8)

1.00

VEGFR-TKIs

Sunitinib, n (%)

29 (53.7)

4 (50.0)

25 (61.0)

1.00

Axitinib, n (%)

8 (14.8)

2 (12.5)

6 (14.6)

1.00

Sorafenib, n (%)

6 (11.1)

1 (12.5)

5 (12.2)

1.00

Pazopanib, n (%)

6 (11.1)

1 (12.5)

5 (12.2)

1.00

Cabozantinib, n (%)

1 (1.9)

1 (12.5)

0

0.24

EF (%), mean (SD)

72.2

67.6 (8.6)

70.7 (6.9)

0.18